Skip to main content

Advertisement

SpringerLink
Log in

Biopharmaceutical benchmarks

  • Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Less than 20 years after the first biopharmaceutical, insulin, was approved, a new generation of products is superseding replacement proteins and enzyme therapies in biotechnology's pipeline.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

References

  1. http://www.panmuregordon.com.

  2. Walsh, G. Biopharmaceuticals, biochemistry and biotechnology. (J. Wiley & Sons, Ltd., Chichester, UK; 1998).

    Google Scholar 

  3. http://www.phrma.org.

  4. http://www.eudra.org/en_home.htm

  5. Rohricht, P. Transgenic protein production; the technology and major players. Biopharm, March (1999), pp. 46–49.

  6. Rohricht, P. Transgenic protein production: process economics. Biopharm, September (1999), pp. 52–54.

  7. Colman, A. Dolly, Polly and other ‘ollys’: Likely impact of cloning technology on biomedical uses of livestock. Genet. Anal. Biomol. Eng. 15, 167–173 (1999).

    Article  CAS  Google Scholar 

  8. Dyer, M. et al. Functional genomics: from genes to new therapies. Drug Disc. Today 4, 109–114 (1999).

    Article  CAS  Google Scholar 

  9. Zweiger, G. Knowledge based discovery in gene expression microarray data; mining the information output of the genome. Trends Biotechnol. 17, 429–436 (1999).

    Article  CAS  Google Scholar 

  10. Wang, J. & Hewick, R. Proteomics in drug discovery. Drug Disc. Today 4, 129–133 (1999).

    Article  Google Scholar 

  11. Blackstock, W. & Weir, M. Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol. 17, 121–127 (1999)

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. lecturer, Industrial Biochemistry Programme, University of Limerick, Ireland

    Gary Walsh

Authors
  1. Gary Walsh
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Walsh, G. Biopharmaceutical benchmarks. Nat Biotechnol 18, 831–833 (2000). https://doi.org/10.1038/78720

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/78720

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation